Welcome to our dedicated page for CURANEX PHARMACEUTICALS news (Ticker: CURX), a resource for investors and traders seeking the latest updates and insights on CURANEX PHARMACEUTICALS stock.
Curanex Pharmaceuticals Inc (NASDAQ: CURX) is a developmental-stage biotechnology company headquartered in Jericho, New York, that focuses on discovering and developing botanical drugs for inflammatory diseases. The Curanex news page on Stock Titan aggregates company press releases, market announcements, and regulatory disclosures so readers can follow how its drug development and corporate activities evolve over time.
News about Curanex often centers on its lead botanical candidate Phyto-N, a single-plant extract with anti-inflammatory properties that the company is advancing for moderate to severe ulcerative colitis and other inflammatory indications. Updates may cover preclinical research progress, plans for FDA-required GLP toxicology and pharmacokinetic studies, and steps toward an Investigational New Drug (IND) submission and Phase I clinical trials.
Investors can also find coverage of capital markets events, such as the pricing and closing of Curanex’s initial public offering on the Nasdaq Capital Market and the exercise of underwriters’ over-allotment options. Additional news items may highlight unregistered sales of equity securities, related-party financing transactions and their repayment, and the company’s engagement of Strategic Investor Relations, LLC to enhance investor communications.
Regulatory and listing-related developments appear in the news flow as well, including SEC filings and Nasdaq notifications. For example, Curanex has reported a Nasdaq notice regarding the minimum bid price requirement and a Form 12b-25 explaining a brief delay in filing a Quarterly Report on Form 10-Q. By reviewing these updates in one place, readers can track how Curanex manages its listing status, financing, and pipeline milestones.
Bookmark this page to monitor Curanex’s official announcements, SEC-related news, and key developments in its botanical drug programs for inflammatory diseases.
Curanex Pharmaceuticals (Nasdaq: CURX) engaged Strategic Investor Relations, LLC on October 22, 2025 to strengthen investor communications and visibility. The firm will support outreach, refine messaging, and highlight Curanex’s botanical drug pipeline targeting ulcerative colitis, atopic dermatitis, and gouty arthritis.
The company's lead Ulcerative Colitis candidate is on track for an IND submission in 2026, and management emphasized regulatory compliance with the FDA and a development approach informed by over 30 years of clinical evidence in China.
Curanex Pharmaceuticals (NASDAQ:CURX), a developmental stage pharmaceutical company, announced the full exercise of the over-allotment option by lead underwriter Dominari Securities LLC following its IPO. The underwriters purchased an additional 562,500 shares at $4.00 per share, raising an extra $2.25 million.
The total gross proceeds from the IPO now amount to $17.25 million through the issuance of 4,312,500 total shares. The offering was led by Dominari Securities LLC, with Pacific Century Securities and Revere Securities as co-underwriters. The registration statement became effective on August 12, 2025.
Curanex Pharmaceuticals (NASDAQ:CURX), a developmental stage pharmaceutical company focused on botanical drugs for inflammatory diseases, has successfully completed its Initial Public Offering (IPO). The company raised $15 million in gross proceeds through the offering of 3,750,000 shares at $4.00 per share.
Trading of CURX shares commenced on the Nasdaq Capital Market on August 26, 2025. The underwriters, led by Dominari Securities LLC, have a 45-day option to purchase up to 562,500 additional shares at the public offering price, less underwriting discounts and expenses.
Curanex Pharmaceuticals (NASDAQ:CURX), a developmental stage pharmaceutical company focused on botanical drugs for inflammatory diseases, has announced the pricing of its initial public offering of 3,750,000 shares at $4.00 per share.
The IPO is expected to raise $15 million in gross proceeds before deducting underwriting costs. Trading will commence on August 26, 2025 on the Nasdaq Capital Market. Underwriters have a 45-day option to purchase up to 562,500 additional shares.
Proceeds will fund the development of their lead product Phyto-N for ulcerative colitis, conduct FDA-required toxicology studies, prepare an IND application, and provide working capital. Dominari Securities leads the underwriting, with Pacific Century Securities and Revere Securities as co-underwriters.
FAQ
What is the current stock price of CURANEX PHARMACEUTICALS (CURX)?
What is the market cap of CURANEX PHARMACEUTICALS (CURX)?
